Please use this identifier to cite or link to this item:
|Title||Evaluation of plasma soluble Human Leukocyte Antigen -G as a Tumor Marker for Breast Cancer patients in Gaza Strip|
|Title in Arabic||تقييم مستضد كريات الدم البيضاء البشرية القابلة للذوبات في البلازما من نوع g كعلامة اوزام لمريضات سرطان الثدي في قطاع غزة|
Background: Soluble Human leukocyte antigen-G (sHLA-G) has been closely associated with diagnosis and prognosis in many types of human cancer. The current study aims to investigate whether or not plasma s HLA-G can be used as a potential biomarker for detection and diagnosis of breast cancer in Gaza strip. Patients and Methods: The study is a case control and carried out in Al-Shifa hospital in Gaza city. sHLA-G plasma levels were determined using a specific sandwich enzyme linked immunosorbent assay (ELISA) on 180 women aged 25-75 years. The study population were divided into two groups; the (case group) consisted of 60 women with breast cancer and receiving anti-cancer treatment (post ) and 60 women who have breast cancer but did not receive chemotherapy (pre), and (control group) consisted of 60 healthy women. CA15-3 and CEA levels were assayed by using the Axsym Immunoassay system. SPSS system was used to analyze the data. Results: Plasma sHLA-G levels were significantly higher in breast cancer patients compared to healthy controls (P<0.001), the Receiver-Operating Characteristic (ROC) curve of sHLA-Gfor discriminating patients with breast cancer (n= 120) from the control group (n= 60) was 0.919 (95% CI = 0.882 - 0.956), and was smaller than those of CA15-3 (0.998, 95% CI = 0.996 -1.00) and CEA (0.985, 95% CI = 0.973 - 0.997). There were significant differences among the Area Under-ROCs(AU-ROCs) of sHLA-G, CA15-3, and CEA (P=0.000; sHLA-G vs. CA15-3, P =0.000; sHLA-G vs. CEA, P = 0.000; CA15-3 vs. CEA, P = 0.000). The cutoff values to differentiate the breast cancer group from the control group were 107 u/ml. The AU-ROCs of sHLA-G, CEA, and CA15-3 for differentiating the group of women who did not receive chemotherapy yet (n = 60) and the group of women who received anti-cancer treatment (n = 60) were 0.998,0.781 and 0.698, respectively(P< 0.001), the cutoff values to differentiate between the two groups were 216 u/ml, 4.2 ng/ml, and 42.45 u/ml, respectively. We also investigate the correlation of sHLA-G with CA15-3 and CEA, the levels of sHLA-G positive significantly correlate with CEA and CA15-3 (r =0.701, P< 0.001 and r =0.666, P< 0.001, respectively) in the total study population. For the correlation of sHLA-G with Hb, the results showed good positive correlations according to Spearman’s roh test. In addition, we found statistically significant differences at 0.05 in sHLA-G, CEA, CA15-3, Hb and WBC between the pre group and post group ( U= 2.00, 179.0, 271.5, 313.50, and 29.00 respectively, p< 0.001). Furthermore, 53 % of breast cancer women were younger than 55 years old. Conclusion: Our study may provide evidence in further support of the application of sHLA-G as a biomarker in body fluids for breast cancer diagnosis and monitoring of breast cancer therapy.
|Publisher||الجامعة الإسلامية - غزة|
|Files in this item|